Plasma GH is a biomarker candidate for predicting outcomes i

A new research paper was published in Oncotarget's Volume 13 on December 6, 2022, entitled, "Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients."

Related Keywords

Massachusetts , United States , Manalm Hassan , Shadim Chamseddine , Ahmed Omar Kaseb , Khaledm Elsayes , Dang Duda , Wasif Rashid , Jeffreys Morris , Rikitai Hatia , Emily Henderson , Atezo Bev , Yehiai Mohamed , Roberta Wolff , Jamesc Yao , Heshamm Amin , Muhammado Awiwi , Lina Altameemi , Aliya Qayyum , Sunyoungs Lee , Armeen Mahvash , Lianchun Xiao , Michigan State University , University Of Pennsylvania , Md Anderson Cancer Center , Harvard Medical School , Perelman School Of Medicine , Cancer Center , Massachusetts General Hospital , Perelman School , Discovery Industry Focus , Bevacizumab , Biomarker , Arcinoma , Growth Hormone , Hepatocellular Carcinoma , Ormone , Dancer , Ncology , Research ,